Direct Renin Inhibition and the Kidney

Renal Function Clinical Trial

Official title:

Direct Renin Inhibition and the Kidney

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01217736
• Other study ID #: VTP-27999-005
• Secondary ID: 2010P001281
• Status: Completed
• Phase: Phase 1
• First received: October 6, 2010
• Last updated: February 26, 2016
• Start date: September 2010
• Est. completion date: November 2011

Study information

• Verified date: February 2016
• Source: Vitae Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to determine the magnitude of the effect of direct renin inhibition by VTP-27999 on renal plasma flow and kidney function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: November 2011
• Est. primary completion date: November 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Healthy adult male or female, 18-75 years of age

• Female subjects must be postmenopausal or surgically sterilized. Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Menopause will be confirmed by plasma serum FSH level at screening between 23.0-116.3 mIU/ml. Female subjects who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing.

• Male subjects, able to father a child, must be willing to use approved birth control methods for 2 weeks following completion of study.

Exclusion Criteria:

• Subjects under 18 and subjects over 75 years

• Diabetes Mellitus and/or kidney disease

• Myocardial infarction, stroke, or cardiovascular revascularization/angioplasty within the last 6 months

• Unstable angina pectoris or CAD requiring treatment with an excluded concomitant medication

• History of/or symptoms consistent with congestive heart failure

• Hypertension

• History of left ventricular ejection fraction < 45%

• Current smokers or nicotine patch

• Pregnant or lactating females

• Cancer or any life threatening illness with expected death within 2 years or by completion of the study

• Serum creatinine >1.4 mg/dl

• Serum potassium <3.5 or >5.2 mmol/L without medication

• Serum albumin < 2.0 g/dL

• Hemoglobin < 11.5 g/dL or Hematocrit < 34%

• Any serum AST >/= 60 or ALT >/= 75 IU/L

• Use of any prescription drugs which may affect the renin-angiotensin-aldosterone system or with known effect on renal hemodynamics are not allowed within 10 days prior to dosing or during the study

• Use of CYP3A4 inhibitors (e.g. Diltiazem, Ketoconazole, Nifedipine, or Verapamil)

• Use of any prescription medication is prohibited within 14 days (or, if known, for at least 5 half-lives, if longer) prior to dosing, unless approved by both the Investigator and the Sponsor

• Use of any over-the-counter (OTC) medication, including herbal products, is prohibited within the 14 days prior to dosing, unless approved by both the Investigator and the Sponsor

• Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing

• A known hypersensitivity or contraindication to the study drugs (Aliskiren) or drugs similar to the study drugs or PAH, and inulin

• Any surgical or medical condition which alters absorption, distribution, metabolism or excretion of drugs or which may jeopardize the patient subject during this study, including gastric bypass

• History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by past medical history

• Acute infections and/or significant illness within 3 weeks of planned enrollment into this study

• Any medical condition in the investigator's opinion, which renders the subject unable to complete the study or which would produce significant risk to the subject

• Administration of any other investigational drug within 30 days of planned dosing in the study

• Poor intravenous (IV) access as determined by the study staff

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Renal Function

Intervention

Drug:
• aliskiren
single dose, tablet
• placebo
single dose, tablet
• VTP-27999
single dose, tablet

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Vitae Pharmaceuticals, Inc.	Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

References & Publications (2)

Barkoudah E, Danser AHJ, van Thiel BS, Fisher NDL, Gregg R, Hollenberg NK. Journal of the American Society of Hypertension 9(4)

Barkoudah E, van Thiel BS, Fisher ND, Gregg RA, Danser AH, Moukarbel GV, Hollenberg NK. Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren. J Hypertens. 2016 Feb 12. [Epub ahead of print] — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	renal plasma flow	as measured by PAH clearance	pre-dose to 6 hours post-dose	No
Secondary	glomerular filtration rate		pre-dose to 6 hours post-dose	No
Secondary	RAAS pathway biomarkers	renin, prorenin, plasma renin activity, ang II	pre-dose to 24 hours post-dose	No
Secondary	VTP-27999 concentrations		pre-dose to 24 hours post-dose	No

External Links

•   maximum renal responses in healthy study participants: VTP-27999 versus aliskiren
•   The influence of VTP-27999 on renal and hormonal responses